Buy Rating on Icon: Navigating Short-term Challenges with Strong Competitive Position and Strategic Initiatives
Michael Ryskin, an analyst from Bank of America Securities, maintained the Buy rating on Icon (ICLR – Research Report). The associated price ...
TD Cowen cuts ICON stock price target to $254, maintains Buy rating
TD Cowen adjusted its financial outlook for ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries.
ICON Public (NASDAQ:ICLR) Receives Outperform Rating from William Blair
ICON Public (NASDAQ:ICLR – Get Free Report)‘s stock had its “outperform” rating reissued by William Blair in a research note ...
Investing8d
ICON stock target cut, maintains buy rating on financial guidance
On Wednesday, Jefferies analyst David Windley adjusted the price target for ICON plc (NASDAQ:ICLR) shares, reducing it to $252 from the previous target of $275, while maintaining a Buy rating on ...
ETF Daily News6d
ICON Public (NASDAQ:ICLR) Given Outperform Rating at Royal Bank of Canada
Royal Bank of Canada reissued their outperform rating on shares of ICON Public (NASDAQ:ICLR – Free Report) in a research report report published on Wednesday morning,Benzinga reports.
Investing9d
ICON plc stock retains Overweight rating amid conservative growth forecasts
On Tuesday, Barclays (LON:BARC) reaffirmed its Overweight rating on ICON plc shares (NASDAQ:ICLR), a $17.2 billion market cap clinical research organization with a P/E ratio of 23.05, maintaining ...